These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32336175)

  • 1. Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability.
    Duy PQ; He M; He Z; Kahle KT
    Expert Opin Ther Targets; 2020 Jul; 24(7):629-637. PubMed ID: 32336175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal K
    McMoneagle E; Zhou J; Zhang S; Huang W; Josiah SS; Ding K; Wang Y; Zhang J
    Acta Pharmacol Sin; 2024 Jan; 45(1):1-22. PubMed ID: 37704745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of KCC2 Mutations in Human Epilepsy Suggests Strategies for Therapeutic Transporter Modulation.
    Duy PQ; David WB; Kahle KT
    Front Cell Neurosci; 2019; 13():515. PubMed ID: 31803025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The suppressive effect of the specific KCC2 modulator CLP290 on seizure in mice.
    Cai J; Wu Z; Wang G; Zhao X; Wang X; Wang BH; Yu J; Liu X; Wang Y
    Epilepsy Res; 2024 Jul; 203():107365. PubMed ID: 38677001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K-Cl cotransporter gene.
    Woo NS; Lu J; England R; McClellan R; Dufour S; Mount DB; Deutch AY; Lovinger DM; Delpire E
    Hippocampus; 2002; 12(2):258-68. PubMed ID: 12000122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Efficacy of the KCC2 Cotransporter Promotes Epileptic Oscillations in a Subiculum Network Model.
    Buchin A; Chizhov A; Huberfeld G; Miles R; Gutkin BS
    J Neurosci; 2016 Nov; 36(46):11619-11633. PubMed ID: 27852771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The KCC2 Cotransporter and Human Epilepsy: Getting Excited About Inhibition.
    Kahle KT; Khanna AR; Duan J; Staley KJ; Delpire E; Poduri A
    Neuroscientist; 2016 Dec; 22(6):555-562. PubMed ID: 27130838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments.
    Löscher W; Puskarjov M; Kaila K
    Neuropharmacology; 2013 Jun; 69():62-74. PubMed ID: 22705273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current view on the functional regulation of the neuronal K(+)-Cl(-) cotransporter KCC2.
    Medina I; Friedel P; Rivera C; Kahle KT; Kourdougli N; Uvarov P; Pellegrino C
    Front Cell Neurosci; 2014; 8():27. PubMed ID: 24567703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression patterns of chloride transporters, Na+-K+-2Cl--cotransporter and K+-Cl--cotransporter, in epilepsy-associated malformations of cortical development.
    Aronica E; Boer K; Redeker S; Spliet WG; van Rijen PC; Troost D; Gorter JA
    Neuroscience; 2007 Mar; 145(1):185-96. PubMed ID: 17207578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures.
    Moore YE; Deeb TZ; Chadchankar H; Brandon NJ; Moss SJ
    Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10166-10171. PubMed ID: 30224498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seizing Control of KCC2: A New Therapeutic Target for Epilepsy.
    Moore YE; Kelley MR; Brandon NJ; Deeb TZ; Moss SJ
    Trends Neurosci; 2017 Sep; 40(9):555-571. PubMed ID: 28803659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing premature KCC2 expression rescues seizure susceptibility and spine morphology in atypical febrile seizures.
    Awad PN; Sanon NT; Chattopadhyaya B; Carriço JN; Ouardouz M; Gagné J; Duss S; Wolf D; Desgent S; Cancedda L; Carmant L; Di Cristo G
    Neurobiol Dis; 2016 Jul; 91():10-20. PubMed ID: 26875662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compromised GABAergic inhibition contributes to tumor-associated epilepsy.
    MacKenzie G; O'Toole KK; Moss SJ; Maguire J
    Epilepsy Res; 2016 Oct; 126():185-96. PubMed ID: 27513374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K
    Tillman L; Zhang J
    Biomed Res Int; 2019; 2019():8941046. PubMed ID: 31240228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Therapeutic Potential of Neuronal K-Cl Co-Transporter KCC2 in Huntington's Disease and Its Comorbidities.
    Andrews K; Josiah SS; Zhang J
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fructose-1,6-diphosphate protects against epileptogenesis by modifying cation-chloride co-transporters in a model of amygdaloid-kindling temporal epilepticus.
    Ding Y; Wang S; Jiang Y; Yang Y; Zhang M; Guo Y; Wang S; Ding MP
    Brain Res; 2013 Nov; 1539():87-94. PubMed ID: 24095797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated downregulation of KCC2 and GABA
    Wan L; Chen L; Yu J; Wang G; Wu Z; Qian B; Liu X; Wang Y
    Biochem Biophys Res Commun; 2020 Nov; 532(3):489-495. PubMed ID: 32892950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KCC2, epileptiform synchronization, and epileptic disorders.
    Di Cristo G; Awad PN; Hamidi S; Avoli M
    Prog Neurobiol; 2018 Mar; 162():1-16. PubMed ID: 29197650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic potential of human SLC12A5 variants causing KCC2 dysfunction.
    Fukuda A; Watanabe M
    Brain Res; 2019 May; 1710():1-7. PubMed ID: 30576625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.